Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 21, 2023 at 03:01 am IST
Share
Nuo Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.232241 million compared to USD 0.03825 million a year ago. Net loss was USD 0.79064 million compared to USD 0.912789 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
For the nine months, revenue was USD 0.41151 million compared to USD 0.03825 million a year ago. Net loss was USD 2.52 million compared to USD 2.21 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.06 a year ago.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.